GlycoMark test results are reported as a quantitative measurement of 1,5-Anhydroglucitol (1,5-AG).
Results 10 or greater are NORMAL. Results less than 10 are ABNORMAL.*
GlycoMark Reference Range:1
|10 - 31 µg/mL*||GlycoMark Normal|
|< 10 µg/mL*||GlycoMark Abnormal|
The following guide describes the interpretation of results:
Refer to the GlycoMark test package insert for additional information.
Print interpretation guide.
* Normal GlycoMark results are lower in females than in males. Refer to gender specific ranges in the product package insert for more information.
Glycomark results represent glycemic control during the prior 1 to 2 weeks. Repeat test in as soon as 2 weeks to reassess glycemic control, response to treatment or compliance.
The information contained herein is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark product insert for more information. The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes. It is not intended to be used to identify patients that will experience complications of diabetes or the likelihood of experiencing complications, nor is it intended to diagnose complications of diabetes.
Values less than the reference range are considered abnormal, and indicate recent hyperglycemic excursions.
Abnormal results are produced by blood glucose levels that exceed the renal threshold. Certain conditions, such as pregnancy, are associated with alterations in the glucose renal threshold, which defines the blood glucose level at which glycosuria occurs.
Abnormal results may also be observed in association with the use of certain medications, such as glucocorticoid steroids and atypical antipsychotics that are associated with an increased occurrence of hyperglycemia and glycosuria.
1Selvin E, et al. Clin Chem. 2014 Nov; 60(11): 1409–1418.
2Selvin E, et al. Diabetes 2016;65:201–208.
3Lee AK, et al. Diabetes Care 2017 Dec; 40(12): 1661-1667.
4Rawlings AM, et al. Diabetes Care 2017 Jul; 40(7): 879-886.
5Nowak N, et al. Diabetologia 2013 Apr; 56(4): 709–713.
6Monnier et al. Diabetes Care 2003'26(3):881-885.
7GlycoMark Test Product Package Insert, Revision G, 2017.
8American Diabetes Association. Medical Management of Type 2 Diabetes, 7th edition, 2012.
9American Diabetes Association. Diabetes Care 2020; 43(Suppl. 1): S66-S76.